Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 17, 2017 07:30 ET | Source: Myriad Genetics, Inc.

Myriad’s BRACAnalysis CDx® Test Successfully Identified Metastatic Breast Cancer Patients with Improved Outcomes from AstraZeneca's PARP Inhibitor, Olaparib

SALT LAKE CITY, Feb. 17, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced new findings from the OlympiAD...
February 17, 2017 07:05 ET | Source: Myriad Genetics, Inc.

Myriad’s Prolaris® Test Significantly Improves the Risk Classification for One Third of Men Diagnosed with Localized Prostate Cancer

SALT LAKE CITY, Feb. 17, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a global leader in personalized medicine, today announced new data demonstrating the utility of the Prolaris®...
February 07, 2017 16:05 ET | Source: Myriad Genetics, Inc.

Myriad Genetics Reports Fiscal Second-Quarter 2017 Financial Results

Second-Quarter 2017 Total Revenues of $196.5 MillionSecond-Quarter 2017 GAAP Diluted EPS of $0.09 and Adjusted EPS of $0.26Company Updates Fiscal Year 2017 Guidance and Issues Fiscal Third-Quarter...
January 24, 2017 16:05 ET | Source: Myriad Genetics, Inc.

Myriad to Announce Fiscal Second-Quarter 2017 Financial Results on February 7, 2017

SALT LAKE CITY, Jan. 24, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN) today announced that it will hold its fiscal second-quarter 2017 sales and earnings conference call with...
January 06, 2017 07:05 ET | Source: Myriad Genetics, Inc.

The EndoPredict® Test Receives Positive Coverage Decisions from Multiple Blue Cross Blue Shield Affiliate Plans

SALT LAKE CITY, Jan. 06, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a global leader in personalized medicine, today announced that multiple Blue Cross Blue Shield (BCBS) affiliate...
January 05, 2017 07:05 ET | Source: Myriad Genetics, Inc.

EndoPredict® Reviewed by Blue Cross Blue Shield Association’s Evidence Street

SALT LAKE CITY, Jan. 05, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a global leader in personalized medicine, today announced that Evidence Street has reviewed EndoPredict®,...
December 28, 2016 07:05 ET | Source: Myriad Genetics, Inc.

Myriad Genetics to Present at the 2017 JP Morgan Healthcare Conference

SALT LAKE CITY, Dec. 28, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN) announced today that Mark C. Capone, president and CEO, Myriad Genetics, is scheduled to present at the 2017 JP...
December 27, 2016 07:05 ET | Source: Myriad Genetics, Inc.

Positive Clinical Utility Results of Crescendo’s Vectra® DA Test for Rheumatoid Arthritis Published in the Journal Arthritis & Rheumatology

SALT LAKE CITY, Dec. 27, 2016 (GLOBE NEWSWIRE) -- Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ:MYGN), today announced that new data on the use of Vectra® DA test...
December 22, 2016 14:02 ET | Source: Myriad Genetics, Inc.

United Rheumatology Issues Clinical Practice Guidelines and Recommends the Vectra® DA Test for Adults with Rheumatoid Arthritis

SALT LAKE CITY, Dec. 22, 2016 (GLOBE NEWSWIRE) -- Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ:MYGN), today announced that United Rheumatology, a leading...
December 09, 2016 07:05 ET | Source: Myriad Genetics, Inc.

The EndoPredict® Test Significantly Outperforms the First-Generation Test in Predicting the Risk of Node-Negative and Node-Positive Breast Cancer Recurrence

SALT LAKE CITY, Dec. 09, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced results of a large head-to-head...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right